Oric Pharmaceuticals (ORIC) Price & Analysis

Compare

369 Followers

ORIC Stock Chart & Stats

Day’s Range― - ―

52-Week Range$3.90 - $14.67

Previous CloseN/A

Volume181.02K

Average Volume (3M)1.02M

Market Cap

$811.33M

Enterprise Value$513.74M

Total Cash (Recent Filing)$282.51M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.57

Next Earnings

Nov 10, 2025

EPS Estimate

-0.39

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.47

Shares Outstanding97,122,986

10 Day Avg. Volume799,661

30 Day Avg. Volume1,020,929

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.63

Enterprise Value/Revenue481.93

Enterprise Value/Gross Profit-1.47K

Enterprise Value/Ebitda-3.45

Forecast

1Y Price Target

$18.00

Price Target Upside81.27% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

Clinical DataORIC-944 updates in prostate cancer show promise, potentially increasing the value of the stock.

Financial PositionORIC announced a concurrent private placement raising $125 million, supporting its financial position.

Bears Say

Risks In Clinical DevelopmentRisks include inability to advance ORIC-114 and ORIC-944 in clinical development, negative clinical data with these pipeline candidates, and delays in moving into pivotal trials in various cancer indications.

Safety ConcernsInvestors focused on the safety profile with a high treatment-related Grade ≥3 adverse event rate of 49%.

Oric Pharmaceuticals News

Oric Pharmaceuticals price target lowered to $19 from $22 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Oric Pharmaceuticals (ORIC) to $19 from $22 and keeps a...

2d ago

ORIC

Oric Pharmaceuticals reports Q2 EPS (47c), consensus (44c)

“In the first half of the year, we’ve continued to make steady progress towards the potential initiation of...

3d ago

ORIC

Oric Pharmaceuticals: Promising Future with Key Trials and Financial Stability Underpinning Buy Rating

Soumit Roy, an analyst from JonesTrading, maintained the Buy rating on Oric Pharmaceuticals. The associated price target remains...

3h ago

ORIC

Oric Pharmaceuticals Faces Potential Setbacks Amid Competitors’ Clinical Trials

Oric Pharmaceuticals Inc (ORIC) has disclosed a new risk, in the Innovation / R&D category. Oric Pharmaceuticals Inc....

2d ago

ORIC

Oric Pharmaceuticals Focuses on Lead Clinical Programs

Oric Pharmaceuticals ( ($ORIC) ) has shared an update. On August 12, 2025, ORIC Pharmaceuticals announced a strategic...

3d ago

ORIC

Oric Pharmaceuticals initiated with a Buy at Ladenburg

Ladenburg initiated coverage of Oric Pharmaceuticals (ORIC) with a Buy rating and $15 price target The firm cites...

1M ago

ORIC

Oric Pharmaceuticals Elects Directors at Annual Meeting

An announcement from Oric Pharmaceuticals ( ($ORIC) ) is now available. On June 11, 2025, Oric Pharmaceuticals held...

2M ago

ORIC

JPMorgan biotech/pharma analysts hold analyst/industry conference call

US SMid Biotech Analyst Rama and US Major & Specialty Pharmaceuticals Analyst Schott, along with Dr. Charles Ryan,...

2M ago

JNJ

PFE

Oric Pharmaceuticals files to sell 19.23M shares of common stock for holders

16:11 EDT Oric Pharmaceuticals (ORIC) files to sell 19.23M shares of common stock for holders Published first on...

2M ago

ORIC

Promising Potential of ORIC-944 in mCRPC Treatment Drives Buy Rating and $22 Price Target

Analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Oric Pharmaceuticals (ORIC – Research Report), retaining...

2M ago

ORIC

Court blocks Trump tariffs, Musk steps away from DOGE: Morning Buzz

The major averages were broadly higher in the early going on the back of Nvidia’s post-earnings rally and...

3M ago

Oric Pharmaceuticals data ‘home run scenario,’ says JPMorgan

JPMorgan views Oric Pharmaceuticals (ORIC)’ Phase 1b dose-escalation combination data for ORIC-944 plus AR inhibitor in metastatic castration-resistant...

3M ago

ORIC

Buy Rating for Oric Pharmaceuticals Driven by Promising ORIC-944 Study Results and Undervaluation

J.P. Morgan analyst Anupam Rama has maintained their bullish stance on ORIC stock, giving a Buy rating today....

3M ago

ORIC

Closing Bell Movers: Nvidia gains 4% on earnings, lifting other semis

In the opening hour of the evening session, U. S. equity futures are gaining following a Q1 earnings...

3M ago

ORIC FAQ

What was Oric Pharmaceuticals’s price range in the past 12 months?

Oric Pharmaceuticals lowest stock price was $3.90 and its highest was $14.67 in the past 12 months.

What is Oric Pharmaceuticals’s market cap?

Oric Pharmaceuticals’s market cap is $811.33M.

When is Oric Pharmaceuticals’s upcoming earnings report date?

Oric Pharmaceuticals’s upcoming earnings report date is Nov 10, 2025 which is in 87 days.

How were Oric Pharmaceuticals’s earnings last quarter?

Oric Pharmaceuticals released its earnings results on Aug 12, 2025. The company reported -$0.47 earnings per share for the quarter, missing the consensus estimate of -$0.443 by -$0.027.

Is Oric Pharmaceuticals overvalued?

According to Wall Street analysts Oric Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Oric Pharmaceuticals pay dividends?

Oric Pharmaceuticals does not currently pay dividends.

What is Oric Pharmaceuticals’s EPS estimate?

Oric Pharmaceuticals’s EPS estimate is -0.39.

How many shares outstanding does Oric Pharmaceuticals have?

Oric Pharmaceuticals has 97,122,986 shares outstanding.

What happened to Oric Pharmaceuticals’s price movement after its last earnings report?

Oric Pharmaceuticals reported an EPS of -$0.47 in its last earnings report, missing expectations of -$0.443. Following the earnings report the stock price went up 3.256%.

Which hedge fund is a major shareholder of Oric Pharmaceuticals?

Currently, no hedge funds are holding shares in ORIC

Oric Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

-43.82%

Trailing 12-Months

Asset Growth

5.46%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Oric Pharmaceuticals

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Oric Pharmaceuticals (ORIC) Earnings & Revenues

Historic Earnings Reports

ORIC Stock 12 Month Forecast

Average Price Target

$18.00

▲(81.27% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","9":"$9","14":"$14","19":"$19","24":"$24"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$23.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,9,14,19,24],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.12,11.11076923076923,12.10153846153846,13.092307692307692,14.083076923076923,15.073846153846153,16.064615384615387,17.055384615384614,18.046153846153846,19.036923076923078,20.027692307692305,21.018461538461537,22.00923076923077,{"y":23,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.12,10.726153846153846,11.332307692307692,11.938461538461539,12.544615384615383,13.150769230769232,13.756923076923076,14.363076923076923,14.96923076923077,15.575384615384616,16.181538461538462,16.787692307692307,17.393846153846155,{"y":18,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.12,10.264615384615384,10.409230769230769,10.553846153846154,10.698461538461538,10.843076923076923,10.987692307692306,11.132307692307691,11.276923076923076,11.42153846153846,11.566153846153846,11.71076923076923,11.855384615384615,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.64,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.61,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.37,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.04,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.41,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.17,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.07,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.42,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.53,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.57,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.47,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.14,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.12,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >